» Articles » PMID: 24801308

Associations of Rhesus and Non-Rhesus Maternal Red Blood Cell Alloimmunization with Stillbirth and Preterm Birth

Overview
Journal Int J Epidemiol
Specialty Public Health
Date 2014 May 8
PMID 24801308
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although the risks of adverse pregnancy outcomes associated with anti-D antibodies are well-recognized, much less is known concerning alloimmunization with other red blood cell antibodies detected during routine maternal screening. To date, most reports of adverse pregnancy outcomes associated with non-anti-D antibodies have been from small case studies. The aim of this study was to examine the associations of maternal alloimmunization with specific red blood cell antibodies and the risks of preterm birth and stillbirth in the Swedish population.

Methods: All antibody screening, outcome and covariate data were obtained through linkages of Swedish national health and data registers. Follow-up in these population-based registers was available up to 31 December 2002. The final study sample consisted of 1,022,569 singleton births from 668,952 mothers during 1987-2002.

Results: In total, 1.3% of the 1,022,569 study pregnancies were alloimmunized. In adjusted logistic regression models, compared with having no antibodies, alloimmunization with anti-D, anti-E, anti-C and anti-c was associated with increased risk of both stillbirth and preterm birth. In addition, anti-Kell was associated with increased risk of preterm birth and anti-Lea with increased risk of stillbirth. Compared with firstborn children, risk of preterm birth associated with alloimmunization was greater in subsequent births

Conclusions: In the largest study to date, alloimmunization with Rhesus, K- and -Lea red blood cell antibodies increased the risk of preterm birth and/or stillbirth. The association of anti-Lea with stillbirth was an unexpected finding. Further study of the consequences of non-anti-D alloimmunization is warranted.

Citing Articles

Hemolytic disease of the fetus and newborn: rapid review of postnatal care and outcomes.

de Winter D, Kaminski A, Tjoa M, Oepkes D, Lopriore E BMC Pregnancy Childbirth. 2023; 23(1):738.

PMID: 37853331 PMC: 10583489. DOI: 10.1186/s12884-023-06061-y.


Evaluation of maternal rhesus blood type as a risk factor in adverse pregnancy outcomes in Korea: a nationwide health insurance database study.

Jin Y, Dong M, Yang S, Lee K, Han S, Seo S Obstet Gynecol Sci. 2020; 63(4):448-454.

PMID: 32689772 PMC: 7393763. DOI: 10.5468/ogs.20004.


Replicated umbilical cord blood DNA methylation loci associated with gestational age at birth.

York T, Latendresse S, Jackson-Cook C, Lapato D, Moyer S, Wolen A Epigenetics. 2020; 15(11):1243-1258.

PMID: 32448018 PMC: 7595591. DOI: 10.1080/15592294.2020.1767277.

References
1.
Wong K, Tse K, Lee A, Mak C, So C . Is antenatal antibody screening worthwhile in Chinese?. Br J Haematol. 1997; 97(4):917-9. DOI: 10.1046/j.1365-2141.1997.1292944.x. View

2.
Lawn J, Yakoob M, Haws R, Soomro T, Darmstadt G, Bhutta Z . 3.2 million stillbirths: epidemiology and overview of the evidence review. BMC Pregnancy Childbirth. 2009; 9 Suppl 1:S2. PMC: 2679408. DOI: 10.1186/1471-2393-9-S1-S2. View

3.
Bowman J, Pollock J, Manning F, Harman C, Menticoglou S . Maternal Kell blood group alloimmunization. Obstet Gynecol. 1992; 79(2):239-44. View

4.
Cousens S, Blencowe H, Stanton C, Chou D, Ahmed S, Steinhardt L . National, regional, and worldwide estimates of stillbirth rates in 2009 with trends since 1995: a systematic analysis. Lancet. 2011; 377(9774):1319-30. DOI: 10.1016/S0140-6736(10)62310-0. View

5.
Filbey D, Hanson U, Wesstrom G . The prevalence of red cell antibodies in pregnancy correlated to the outcome of the newborn: a 12 year study in central Sweden. Acta Obstet Gynecol Scand. 1995; 74(9):687-92. DOI: 10.3109/00016349509021175. View